European Handbook of Dermatological Treatments 2003
DOI: 10.1007/978-3-662-07131-1_49
|View full text |Cite
|
Sign up to set email alerts
|

Leishmaniasis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2005
2005
2005
2005

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 16 publications
0
2
0
Order By: Relevance
“…Amphotericin B is a second‐line drug administered by slow intravenous infusion in intractable cases and resistant mucosal disease. The requirement for parenteral administration, frequent monitoring, prolonged treatment, and dangerous side‐effects of the above agents have prompted the search for more convenient and less costly treatment modalities, as shown in Table 2 1,2,6–8 …”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Amphotericin B is a second‐line drug administered by slow intravenous infusion in intractable cases and resistant mucosal disease. The requirement for parenteral administration, frequent monitoring, prolonged treatment, and dangerous side‐effects of the above agents have prompted the search for more convenient and less costly treatment modalities, as shown in Table 2 1,2,6–8 …”
Section: Discussionmentioning
confidence: 99%
“…Old World cutaneous leishmaniasis is a protozoan disease transmitted through the bite of a sandfly infected with Leishmania parasites. It displays a variety of clinical manifestations that depend both on the infecting Leishmania species and on the immune response of the host 1 …”
Section: Introductionmentioning
confidence: 99%